Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
Oncologist
; 15(9): 1016-22, 2010.
Article
em En
| MEDLINE
| ID: mdl-20798191
ABSTRACT
PURPOSE:
Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes.METHODS:
This placebo-controlled, double-blinded trial enrolled rash-free patients starting an EGFR inhibitor. Patients were randomly assigned to sunscreen with a sun protection factor of 60 applied twice a day for 28 days versus placebo. They were then monitored for rash and quality of life (Skindex-16) during the 4-week intervention and for an additional 4 weeks.RESULTS:
Fifty-four patients received sunscreen, and 56 received placebo; the arms were balanced at baseline. During the 4-week intervention, physician-reported rash occurred in 38 (78%) and 39 (80%) sunscreen-treated and placebo-exposed patients, respectively (p = 1.00); no significant differences in rash rates emerged over the additional 4 weeks. There were no significant differences in rash severity, and patient-reported outcomes of rash yielded similar conclusions. Adjustment for sun intensity by geographical zone, season, and use of photosensitivity medications did not yield a significant difference in rash across study arms (p = .20). Quality of life scores declined but remained comparable between arms.CONCLUSIONS:
Sunscreen, as prescribed in this trial, did not prevent or attenuate EGFR inhibitor-induced rash.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quinazolinas
/
Protetores Solares
/
Exantema
/
Receptores ErbB
/
Anticorpos Monoclonais
/
Neoplasias
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article